|
|
| | OTAVA-BB 1217676 Basic information |
| Product Name: | OTAVA-BB 1217676 | | Synonyms: | 7-NITRO-3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE;OTAVA-BB 1217676;7-Nitro-3,4-dihydro-2H-1,4-benzoxazine;7-Nitro-3,4-dihydro-2H-1,4-benzooxazine;7-Nitro-3,4-dihydrobenzo[1,4]oxazine;7-Nitro-3,4-dihydro-2H-benzo[1,4]oxazine;2H-1,4-Benzoxazine, 3,4-dihydro-7-nitro-;7-Nitro-3,4-dihydro-2H-1,4-benzoxazine,97% | | CAS: | 120711-81-1 | | MF: | C8H8N2O3 | | MW: | 180.16 | | EINECS: | | | Product Categories: | | | Mol File: | 120711-81-1.mol |  |
| | OTAVA-BB 1217676 Chemical Properties |
| Melting point | 187-188° | | Boiling point | 341.6±42.0 °C(Predicted) | | density | 1.332±0.06 g/cm3(Predicted) | | storage temp. | Keep in dark place,Inert atmosphere,Room temperature | | pka | 0.23±0.20(Predicted) | | Appearance | Light yellow to yellow Solid | | Water Solubility | Sparingly soluble in water (0.76 g/L at 25°C). | | CAS DataBase Reference | 120711-81-1 |
| Hazard Codes | T | | Risk Statements | 25 | | Safety Statements | 45 | | RIDADR | UN 2811 6.1 / PGIII | | HazardClass | IRRITANT | | HS Code | 2934999090 |
| | OTAVA-BB 1217676 Usage And Synthesis |
| Uses | 7-Nitro-3,4-dihydro-2H-1,4-benzooxazine can be used as pain drugs to prevent and treat chronic pain. | | Synthesis | The general procedure for the synthesis of 7-nitro-3,4-dihydro-2H-1,4-benzisoxazin-3-one from 7-nitro-2H-1,4-benzisoxazin-3-one was as follows: 7-nitro-4H-benzo[1,4]oxazin-3-one (2.00 g, 10.3 mmol) was dissolved in tetrahydrofuran (THF, 10 mL), and borane-THF complex was added subsequently ( 1.0 M solution of THF, 35 mL). The reaction mixture was heated to reflux for 30 min, then cooled to 0 °C and the reaction was quenched with 1 N hydrochloric acid (20 mL). After continued stirring for 30 min, the reaction solution was concentrated to 1/10 of the original volume. the orange solid product was collected by filtration, washed with water and dried under vacuum to afford 7-nitro-3,4-dihydro-2H-1,4-benzisoxazine (1.66 g, 89% yield). The mass spectrum (electrospray positive ion mode) showed m/z 181.1 ([M+H]+) and the mass spectrum (electrospray negative ion mode) showed m/z 179.2 ([M-H]-).1H NMR (400 MHz, DMSO-d6) data were as follows: δ 7.68 (dd, 1H, J = 8.8, 2.6 Hz), 7.53 (s, 1H), 7.47 (d , 1H, J = 2.6 Hz), 6.63 (d, 1H, J = 9.2 Hz), 4.15 (t, 2H, J = 4.4 Hz), 3.44-3.40 (m, 2H). | | References | [1] Journal of Medicinal Chemistry, 2007, vol. 50, # 10, p. 2486 - 2496 [2] Patent: WO2006/66174, 2006, A1. Location in patent: Page/Page column 52-53 [3] Patent: US2010/9975, 2010, A1. Location in patent: Page/Page column 35 [4] Journal of the American Chemical Society, 2014, vol. 136, # 38, p. 13277 - 13282 [5] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 13, p. 3821 - 3830 |
| | OTAVA-BB 1217676 Preparation Products And Raw materials |
|